Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma

Jean-Baptiste Trouiller (), Georgios F. Nikolaidis, Bérengère Macabeo, Nicolas Meyer, Laetitia Gerlier, Max Schlueter and Philippe Laramee
Additional contact information
Jean-Baptiste Trouiller: Pierre Fabre Laboratories
Georgios F. Nikolaidis: IQVIA Ltd
Bérengère Macabeo: Pierre Fabre Laboratories
Nicolas Meyer: Cabinet médical, Clinique Médipôle Garonne
Laetitia Gerlier: IQVIA Ltd
Max Schlueter: IQVIA Ltd
Philippe Laramee: Pierre Fabre Laboratories

The European Journal of Health Economics, 2024, vol. 25, issue 4, No 7, 653 pages

Abstract: Abstract Objective The objective of this study was to determine the cost-effectiveness of encorafenib with binimetinib (EncoBini) as compared to other targeted double combination therapies, namely dabrafenib with trametinib (DabraTrame) and vemurafenib with cobimetinib (VemuCobi), for the treatment of BRAF V600-mutant unresectable or metastatic melanoma (MM) from the French payer perspective. Methods A partitioned survival model was developed considering a lifetime horizon. The model structure simulated the clinical pathway of patients with BRAF V600-mutant MM. Clinical effectiveness and safety inputs were sourced from the COLUMBUS trial, a network meta-analysis and published literature. Costs, resource use, and the quality of life inputs were obtained from the literature and appropriate French sources. Results Over a lifetime horizon, EncoBini was associated, on average, with reduced costs and increased quality adjusted life years (QALYs), dominating both targeted double combination therapies. For a willingness-to-pay threshold of €90,000 per QALY, the probability of EncoBini being cost-effective against either comparator remained above 80%. The most influential model parameters were the hazard ratios for the overall survival of EncoBini vs DabraTrame and VemuCobi, the pre- and post-progression utility values, as well as treatment dosages and the relative dose intensity of all interventions. Conclusion EncoBini is associated with reduced costs and increased QALYs, dominating other targeted double combination therapies (DabraTrame, VemuCobi) for patients with BRAF V600-mutant MM in France. EncoBini is a highly cost-effective intervention in MM.

Keywords: Encorafenib; Unresectable or metastatic melanoma; BRAF; Cost-effectiveness; Economic analysis; QALY (search for similar items in EconPapers)
Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-023-01614-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:25:y:2024:i:4:d:10.1007_s10198-023-01614-6

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-023-01614-6

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().